Gossamer Bio (NASDAQ:GOSS – Get Free Report) and Quantum Biopharma (NASDAQ:QNTM – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.
Insider & Institutional Ownership
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Gossamer Bio and Quantum Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gossamer Bio | -235.00% | N/A | -112.04% |
| Quantum Biopharma | N/A | -582.23% | -184.20% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gossamer Bio | $48.47 million | 0.84 | -$170.37 million | ($0.70) | -0.25 |
| Quantum Biopharma | N/A | N/A | -$26.17 million | ($5.49) | -0.56 |
Quantum Biopharma has lower revenue, but higher earnings than Gossamer Bio. Quantum Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Gossamer Bio and Quantum Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gossamer Bio | 2 | 3 | 4 | 0 | 2.22 |
| Quantum Biopharma | 1 | 0 | 1 | 0 | 2.00 |
Gossamer Bio presently has a consensus target price of $3.20, suggesting a potential upside of 1,752.92%. Quantum Biopharma has a consensus target price of $8.00, suggesting a potential upside of 159.74%. Given Gossamer Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than Quantum Biopharma.
Volatility and Risk
Gossamer Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Summary
Gossamer Bio beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
